Table 1 Baseline characteristics of the 802 patients with chronic hepatitis B at the time of liver biopsy: comparison between the training set and the validation set
Variables | The training cohort (n = 401) | The validation cohort (n = 401) | All patients (n = 802) |
|---|---|---|---|
Age (years) | 33 (26.5–41) | 36 (29–42) | 34 (27–41) |
Sex (male n, %) | 322 (80.2%) | 318 (79.3%) | 640 (79.8%) |
Weight (kg) | 62 (56–68) | 61 (56–66) | 61 (56–67) |
RBC (1012/L) | 4.8 (4.3–5.5) | 4.6 (4.3–5) | 4.7 (4.3–5.3) |
WBC (109/L) | 5.13 ± 1.23 | 5.24 ± 1.41 | 5.19 ± 1.32 |
PLT (109/L) | 144 (110–193) | 138 (111–176) | 140 (110–86.25) |
HB (g/L) | 140 (130–153) | 139 (125–150.5) | 139 (128–152) |
TG (mmol/L) | 1.2 (0.9–1.5) | 1.2 (0.9–1.4) | 1.2 (0.9–1.4) |
TC (mmol/L) | 4.2 (3.6–4.9) | 4.2 (3.6–4.65) | 4.2 (3.6–4.7) |
ALT (IU/L) | 75 (50–142.5) | 62 (42–101.5) | 68 (45–121) |
AST (IU/L) | 56 (37.5–101.5) | 50 (34–75) | 51 (35–86) |
GGT (IU/L) | 54 (29–111) | 56 (35–82) | 54 (32–93) |
ALP (IU/L) | 79 (64.5–108) | 79 (64–100) | 78 (63.75–104.25) |
TB (μmol/L) | 14.5 (10.95–20.2) | 15.3 (12.3–19.85) | 15 (11.5–20.125) |
DB (μmol/L) | 5 (3.5–8.3) | 5 (3.9–6.95) | 5 (3.6–7.4) |
ALB (g/L) | 41 (37.85–46) | 41 (38–44) | 42 (38–45.1) |
AFP (ng/mL) | 3.8 (2.6–7.25) | 4.2 (3.05–5.9) | 3.9 (2.8–6.7) |
PT (s) | 12.5 (11.75–13.4) | 12.3 (11.7–13.2) | 12.3 (11.7–13.2) |
HBVDNA (log10 copies/mL) | 5.69 (3.34–6.92) | 6.37 (3.67–7.52) | 5.84 (3.41–7.08) |
Grading of liver necroinflammatory activity | |||
G0–1:HAI (0–3) (n, %) | 163 (40.6%) | 170 (42.4%) | 333 (41.5%) |
G2:HAI (4–8) (n, %) | 119 (29.7%) | 116 (28.9%) | 235 (29.3%) |
G3:HAI (9–12) (n, %) | 91 (22.7%) | 88 (21.9%) | 179 (22.3%) |
G4:HAI (13–18) (n, %) | 28 (7.0%) | 27 (6.7%) | 55 (6.9%) |